Answers are grounded in this paper and cite their sources.
Analysis shows no increased risk of respiratory syncytial virus severity in children vaccinated with nirsevimab, suggesting its safety.
Nirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized children immunized with nirsevimab more than 6 months prior. No significant differences were found compared with nonimmunized children. Findings suggest no increased risk in the following season, supporting nirsevimab’s safety as a preventive strategy.
No takes yet. Share an insight, caveat, or question.
González‐Bertolín et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: